Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapport Therapeutics (RAPP) Total Non-Current Liabilities (2023 - 2024)

Rapport Therapeutics (RAPP) has 2 years of Total Non-Current Liabilities data on record, last reported at $74000.0 in Q4 2024.

  • On a quarterly basis, Total Non-Current Liabilities fell 99.28% to $74000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $74000.0, a 99.28% decrease, with the full-year FY2024 number at $74000.0, down 99.28% from a year prior.
  • Total Non-Current Liabilities reached $74000.0 in Q4 2024 per RAPP's latest filing, down from $10.3 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for RAPP hit a ceiling of $10.3 million in Q4 2023 and a floor of $74000.0 in Q4 2024.